Preparation, characterization,and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model

Hazem Ali, Irina Kalashnikova, Mark White, Michael Sherman, Erik Rytting

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89%. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume454
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Nanoparticles
Dexamethasone
Particle Size
Pharmaceutical Preparations
Permeability
Mothers
Cryoelectron Microscopy
Congenital Adrenal Hyperplasia
In Vitro Techniques
Trophoblasts
Transmission Electron Microscopy
X-Ray Diffraction
Placenta
Fetus
High Pressure Liquid Chromatography
Cell Line

Keywords

  • BeWo cells
  • Congenital adrenal hyperplasia
  • Dexamethasone
  • Nanoparticles
  • Placenta
  • Pregnancy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{891526f79d5c4f9992de975cfe774618,
title = "Preparation, characterization,and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model",
abstract = "The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89{\%}. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.",
keywords = "BeWo cells, Congenital adrenal hyperplasia, Dexamethasone, Nanoparticles, Placenta, Pregnancy",
author = "Hazem Ali and Irina Kalashnikova and Mark White and Michael Sherman and Erik Rytting",
year = "2013",
doi = "10.1016/j.ijpharm.2013.07.010",
language = "English (US)",
volume = "454",
pages = "149--157",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Preparation, characterization,and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model

AU - Ali, Hazem

AU - Kalashnikova, Irina

AU - White, Mark

AU - Sherman, Michael

AU - Rytting, Erik

PY - 2013

Y1 - 2013

N2 - The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89%. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.

AB - The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89%. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.

KW - BeWo cells

KW - Congenital adrenal hyperplasia

KW - Dexamethasone

KW - Nanoparticles

KW - Placenta

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84884163096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884163096&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2013.07.010

DO - 10.1016/j.ijpharm.2013.07.010

M3 - Article

VL - 454

SP - 149

EP - 157

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -